- Home
- MCHX vs IMMX Comparison
MCHX vs IMMX Comparison
Compare MCHX & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCHX
- IMMX
- Stock Information
- Founded
- MCHX 2003
- IMMX 2014
- Country
- MCHX United States
- IMMX United States
- Employees
- MCHX N/A
- IMMX N/A
- Industry
- MCHX Business Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- MCHX Consumer Discretionary
- IMMX Health Care
- Exchange
- MCHX Nasdaq
- IMMX Nasdaq
- Market Cap
- MCHX 84.3M
- IMMX 82.6M
- IPO Year
- MCHX 2004
- IMMX 2021
- Fundamental
- Price
- MCHX $1.83
- IMMX $3.67
- Analyst Decision
- MCHX
- IMMX Strong Buy
- Analyst Count
- MCHX 0
- IMMX 1
- Target Price
- MCHX N/A
- IMMX $8.00
- AVG Volume (30 Days)
- MCHX 37.3K
- IMMX 797.4K
- Earning Date
- MCHX 11-14-2025
- IMMX 11-07-2025
- Dividend Yield
- MCHX N/A
- IMMX N/A
- EPS Growth
- MCHX N/A
- IMMX N/A
- EPS
- MCHX N/A
- IMMX N/A
- Revenue
- MCHX $47,534,000.00
- IMMX N/A
- Revenue This Year
- MCHX N/A
- IMMX N/A
- Revenue Next Year
- MCHX $7.56
- IMMX N/A
- P/E Ratio
- MCHX N/A
- IMMX N/A
- Revenue Growth
- MCHX N/A
- IMMX N/A
- 52 Week Low
- MCHX $1.26
- IMMX $1.34
- 52 Week High
- MCHX $2.40
- IMMX $4.00
- Technical
- Relative Strength Index (RSI)
- MCHX 39.44
- IMMX 73.55
- Support Level
- MCHX $1.73
- IMMX $2.31
- Resistance Level
- MCHX $1.89
- IMMX $4.00
- Average True Range (ATR)
- MCHX 0.09
- IMMX 0.31
- MACD
- MCHX -0.00
- IMMX 0.10
- Stochastic Oscillator
- MCHX 12.92
- IMMX 86.39
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.